Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 19/20 | 1.00 |
| ▸ | SRC | P12931 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 15/20 | 0.75 |
| ▸ | FGFR4 | P22455 | 12/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 11/20 | 0.75 |
| ▸ | FGFR3 | P22607 | 11/20 | 0.75 |
| ▸ | FLT1 | P17948 | 9/20 | 0.75 |
| ▸ | FLT4 | P35916 | 9/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16868903 | 0.82 | FGFR1 (1.00) | FGFR1SRCKDRFGFR4FGFR2 | |
| SCHEMBL15434030 | 0.81 | FGFR4 (1.00) | FGFR1SRCKDRFGFR4FGFR2 | |
| SCHEMBL23314947 | 0.81 | FGFR4 (0.88) | FGFR1SRCKDRFGFR4FGFR2 | |
| SCHEMBL30737915 | 0.80 | FGFR1 (1.00) | FGFR1KDRFGFR4FGFR2FGFR3 | |
| SCHEMBL26928578 | 0.80 | FGFR1 (1.00) | FGFR1KDRFGFR4FGFR2FGFR3 | |
| SCHEMBL1248489 | 0.78 | FGFR1 (1.00) | FGFR1SRCKDRFGFR4FGFR2 | |
| SCHEMBL29366761 | 0.78 | FGFR1 (1.00) | FGFR1SRCKDRFGFR4FGFR2 | |
| SCHEMBL22532383 | 0.76 | FGFR1 (0.74) | FGFR1SRCKDRFGFR4FGFR2 | |
| SCHEMBL29390330 | 0.76 | FGFR1 (0.74) | FGFR1SRCKDRFGFR4FGFR2 | |
| SCHEMBL31648262 | 0.73 | FGFR1 (0.76) | FGFR1SRCKDRFGFR4FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975620-A2 | Three hybrid assay system | GPC Biotech AG (DE) | 2008-10-01 | — | — | EP | disclosed |
| US-20080125362-A1 | Method of screening compound preventing cells from infection with Hepatitis C virus (HCV) | JAPAN TOBACCO INC. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080125362-A1 | Method of screening compound preventing cells from infection with Hepatitis C virus (HCV) | JAPAN TOBACCO INC. (JP) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125362-A1 | Method of screening compound preventing cells from infection with Hepatitis C virus (HCV) | HAVCR2, FGFR1, FGFR2 | FGFR1 2/4885SRC 119/4885KDR 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.